Bristol Myers Squibb (BMS) has announced a strategic partnership with Hengrui Pharma to co-develop 13 early-stage programs across oncology, hematology, and immunology, with the collaboration potentially generating over $15.2 billion for Hengrui. This agreement encompasses four oncology/hematology assets from Hengrui, four immunology assets from BMS, and five innovative candidates to be jointly discovered by both companies.
The collaboration aims to leverage BMS’s global clinical development capabilities, regulatory expertise, and commercial scale alongside Hengrui’s efficient early-stage development and discovery engine. Hengrui will lead early clinical development to expedite proof of concept for these programs, with options for co-development and commercialization activities globally.
Financially, BMS will pay Hengrui up to $950 million over two years, including a $600 million upfront payment. The collaboration’s total potential value includes milestone achievements and tiered royalties on net sales outside Hengrui’s operational territories. This partnership reflects BMS’s strategic focus on enhancing its pipeline amid impending patent expirations for key products, as the company seeks to mitigate revenue losses and drive growth in the coming decade.
Start your 7-day trial and see what the database can do →
